Madrigal Pharmaceuticals, Inc. MDGL
We take great care to ensure that the data presented and summarized in this overview for MADRIGAL PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MDGL
View all-
Janus Henderson Group PLC London, X02.21MShares$668 Million0.42% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.1MShares$635 Million39.89% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.02MShares$612 Million10.84% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$603 Million10.82% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$598 Million7.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.69MShares$511 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.43MShares$432 Million0.01% of portfolio
-
State Street Corp Boston, MA759KShares$230 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD543KShares$164 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA421KShares$127 Million0.01% of portfolio
Latest Institutional Activity in MDGL
Top Purchases
Top Sells
About MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Insider Transactions at MDGL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2025
|
Kenneth Bate Director |
BUY
Grant, award, or other acquisition
|
Direct |
715
+21.39%
|
-
|
|
Jun 20
2025
|
Richard S Levy Director |
BUY
Grant, award, or other acquisition
|
Direct |
715
+3.26%
|
-
|
|
Jun 20
2025
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
2,860
+0.42%
|
-
|
|
Jun 20
2025
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
203
+15.62%
|
-
|
|
Jun 20
2025
|
Paul A Friedman Director |
BUY
Grant, award, or other acquisition
|
Direct |
715
+0.38%
|
-
|
|
Jun 20
2025
|
James M Daly Director |
BUY
Grant, award, or other acquisition
|
Direct |
715
+21.39%
|
-
|
|
May 15
2025
|
David Soergel Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,545
+50.0%
|
-
|
|
Apr 10
2025
|
Richard S Levy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,470
+31.62%
|
$615,550
$65.06 P/Share
|
|
Mar 13
2025
|
Fred B Craves Director |
SELL
Open market or private sale
|
Direct |
7,742
-0.27%
|
$2,523,892
$326.58 P/Share
|
|
Mar 13
2025
|
Fred B Craves Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,742
+2.12%
|
$503,230
$65.06 P/Share
|
|
Mar 12
2025
|
Fred B Craves Director |
SELL
Open market or private sale
|
Direct |
7,728
-0.44%
|
$2,565,696
$332.58 P/Share
|
|
Mar 12
2025
|
Fred B Craves Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,728
+1.07%
|
$680,064
$88.06 P/Share
|
|
Mar 10
2025
|
Mardi Dier SVP and CFO |
SELL
Open market or private sale
|
Direct |
258
-2.41%
|
$83,334
$323.04 P/Share
|
|
Mar 10
2025
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
894
+50.0%
|
-
|
|
Mar 05
2025
|
William John Sibold President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
13,066
+10.02%
|
-
|
|
Mar 05
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
2,061
+26.25%
|
-
|
|
Mar 05
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
14,113
-14.66%
|
$4,798,420
$340.42 P/Share
|
|
Mar 05
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
14,113
+34.14%
|
$1,227,831
$87.5 P/Share
|
|
Mar 05
2025
|
Mardi Dier SVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
3,784
+26.13%
|
-
|
|
Mar 05
2025
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
4,382
+0.94%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 49.4K shares |
|---|---|
| Exercise of conversion of derivative security | 135K shares |
| Open market or private sale | 99.9K shares |
|---|---|
| Bona fide gift | 15K shares |